Supernus Pharmaceuticals price to free cash flow SUPN

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: 126×
10-year median: 15.2×
Against its 10-year history: 98th; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.5× to 149×
Peer median: 9.6×

Supernus Pharmaceuticals' price to free cash flow is 126× as of Oct 23, 2026.

That is above its ten-year median of 15.2×, higher than on 98% of days in the last ten years.

Over that time it ranged from 5.5× in Oct 2020 to 149× in Aug 2026.

The median for 10 large drugmakers of a similar size is 9.6×.

Price to free cash flow over time

median 15.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	126×	31.3×	149×
2025	41.8×	10.0×	41.8×
2024	11.9×	11.0×	17.1×
2023	17.0×	10.0×	25.0×
2022	14.0×	11.7×	18.3×
2021	14.3×	8.6×	16.5×
2020	9.1×	5.5×	11.2×
2019	9.4×	8.6×	16.8×
2018	12.9×	12.4×	24.5×
2017	20.1×	18.8×	47.0×
2016	44.1×	23.2×	45.7×
2015	36.9×	14.6×	85.0×

Against its peers

Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
SUPNSupernus Pharmaceuticals	126×
PBHPrestige Consumer Healthcare	9.6×
HRMYHarmony Biosciences	n/m
NRIXNurix Therapeutics	7.5×
ANIPANI Pharmaceuticals	9.6×
PAHCPhibro Animal Health	160×
OGNOrganon	6.4×
LQDALiquidia	25.3×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	8.1×
ARQTArcutis Biotherapeutics	100×
Peer median	9.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Supernus Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.